Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Additional Articles by the Author
Phoebe Starr
Breast Cancer
Radiation May Be Safely Omitted in Favorable-Risk Breast Cancer Patients Aged 50 to 69 Years
Read More
Conference Highlights ASCO
,
Lung Cancer
Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC
Phoebe Starr
Read More
Prostate Cancer
,
Conference Highlights ASCO
¹⁷⁷Lu-PSMA-617 Prolongs Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
Phoebe Starr
Read More
Renal-Cell Carcinoma
,
Conference Highlights ASCO
Adjuvant Pembrolizumab Therapy Significantly Extends Disease-Free Survival in Patients with Clear-Cell Renal-Cell Carcinoma
Phoebe Starr
Read More
Prostate Cancer
¹⁷⁷Lu-PSMA-617 Superior to Cabazitaxel in Metastatic Prostate Cancer
Phoebe Starr
Read More
Momelotinib, a Novel JAK Inhibitor, Makes Inroads in Intermediate- or High-Risk Myelofibrosis
Phoebe Starr
Read More
Leukemia
First-Line Fixed-Duration Ibrutinib plus Venetoclax Therapy Leads to Deep Remissions in Patients with Chronic Lymphocytic Leukemia
Phoebe Starr
Read More
Emerging Therapies
Novel Target: RARA Agonist plus Azacitidine Active in Relapsed or Refractory Acute Myeloid Leukemia
Phoebe Starr
Read More
Leukemia
Asciminib, First-in-Class STAMP Inhibitor, Superior to Bosutinib in Chronic-Phase CML
Phoebe Starr
Read More
Graft-versus-Host Disease
Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results
Phoebe Starr
Read More
1
2
3
4
Page 1 of 9
Results 1 - 10 of 89